Loading
A phase 2 trial of Nivolumab, FLOT, CAPOX in metastatic cancer, run by I-Mab Biopharma US Limited, now recruiting.
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) is a phase 2 interventional study registered as NCT07432295 by I-Mab Biopharma US Limited, with 180 participants planned, started 2026-02-11 and due to reach its primary completion in 2030-03. Interventions recorded: Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin. Conditions listed: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Nivolumab, Metastatic cancer (cancer that has spread).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Nivolumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Capecitabine.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Capecitabine.
Shares CAPOX (capecitabine, oxaliplatin), Capecitabine, Nivolumab, Metastatic cancer (cancer that has spread).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Capecitabine.